NASDAQ:CRVS

Corvus Pharmaceuticals (CRVS) Stock Forecast, Price & News

$1.46

+0.05 (+3.55%)

(As of 09/29/2023 ET)

Compare

Today's Range: $1.41
▼
$1.52
50-Day Range: $1.41
▼
$2.42
52-Week Range: $0.61
▼
$4.19

Volume: 76,102 shs
Average Volume: 364,234 shs
Market Capitalization: $71.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.63

Corvus Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 353.8% Upside
$6.63 Price Target
Short Interest: Bearish
4.94% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.44
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.57) to ($0.56) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

677th out of 972 stocks

Pharmaceutical Preparations Industry

321st out of 449 stocks

3.4

Analyst's Opinion

Consensus Rating
Corvus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.63, Corvus Pharmaceuticals has a forecasted upside of 353.8% from its current price of $1.46.
Amount of Analyst Coverage
Corvus Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.94% of the float of Corvus Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Corvus Pharmaceuticals has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Corvus Pharmaceuticals has recently increased by 32.85%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Corvus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Corvus Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CRVS.

2.5

News and Social Media Coverage

News Sentiment
Corvus Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Corvus Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 40 people have searched for CRVS on MarketBeat in the last 30 days. This is a decrease of -5% compared to the previous 30 days.
MarketBeat Follows
2 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Corvus Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
31.30% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 39.79% of the stock of Corvus Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Corvus Pharmaceuticals are expected to grow in the coming year, from ($0.57) to ($0.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Corvus Pharmaceuticals is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Corvus Pharmaceuticals is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Corvus Pharmaceuticals has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Corvus Pharmaceuticals (NASDAQ:CRVS) Stock

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

CRVS Price History

30 days | 90 days | 365 days | Advanced Chart

CRVS Stock News Headlines

October 1, 2023 | finance.yahoo.com

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

September 12, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI), Arcutis Biotherapeutics (ARQT) and Corvus Pharmaceuticals (CRVS)

October 1, 2023 | Behind the Markets (Ad)

AI Creates New Cancer Drug - In Just 30 Days!

On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...

September 8, 2023 | fool.com

Corvus Pharmaceuticals (NASDAQ: CRVS)

September 7, 2023 | msn.com

Cantor Fitzgerald Reiterates Corvus Pharmaceuticals (CRVS) Overweight Recommendation

September 6, 2023 | finance.yahoo.com

Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

August 18, 2023 | markets.businessinsider.com

Corvus Pharmaceuticals Eyes Expansion Of Blood Cancer Therapy but Resource Limitations Pose Challenge: Oppenheimer

August 8, 2023 | finance.yahoo.com

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

October 1, 2023 | Behind the Markets (Ad)

AI Creates New Cancer Drug - In Just 30 Days!

August 1, 2023 | msn.com

Circling Back On Corvus Pharmaceuticals

August 1, 2023 | finance.yahoo.com

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023

July 6, 2023 | finance.yahoo.com

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)

June 29, 2023 | finance.yahoo.com

Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

June 29, 2023 | finance.yahoo.com

Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

June 15, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Cue Biopharma (CUE) and Corvus Pharmaceuticals (CRVS)

June 15, 2023 | seekingalpha.com

Aldeyra, Bioventus top healthcare gainers; Mersana, Bone Biologics among losers

June 4, 2023 | finance.yahoo.com

Individual investors among Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) largest shareholders, saw gain in holdings value after stock jumped 23% last week

May 31, 2023 | finance.yahoo.com

Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 30, 2023 | msn.com

Ladenburg Thalmann Maintains Corvus Pharmaceuticals (CRVS) Buy Recommendation

May 26, 2023 | finance.yahoo.com

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

May 17, 2023 | finance.yahoo.com

Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma

May 12, 2023 | seekingalpha.com

Corvus Pharmaceuticals: Targeting $1 Billion/Year U.S. T-Cell Lymphoma Market

May 12, 2023 | finance.yahoo.com

Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why

May 10, 2023 | finanznachrichten.de

Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

May 10, 2023 | benzinga.com

Why Are Corvus Pharmaceuticals Trading Higher Today

May 9, 2023 | msn.com

Cantor Fitzgerald Maintains Corvus Pharmaceuticals (CRVS) Overweight Recommendation

April 20, 2023 | finance.yahoo.com

Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023

See More Headlines

Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRVS Company Calendar

Last Earnings: 8/08/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CRVS
CUSIP: N/A
CIK: 1626971
Web: www.corvuspharma.com
Phone: (650) 900-4520
Fax: N/A
Employees: 29
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.63
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $3.50
Forecasted Upside/Downside: +353.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-41,310,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -71.23%
Return on Assets: -58.94%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.82
Quick Ratio: 4.82

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.21 per share
Price / Book: 1.21

Miscellaneous

Outstanding Shares: 48,970,000
Free Float: 33,640,000
Market Cap: $71.50 million
Optionable: Not Optionable
Beta: 0.98

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Richard A. Miller M.D. (Age 72)
Co-Founder, Pres, CEO & Chairman
Comp: $306k

Dr. Peter A. Thompson FACP (Age 63)
M.D., Co-Founder & Independent Director
Comp: $47k

Mr. Leiv Lea (Age 69)
Chief Financial Officer
Comp: $388.73k

Dr. William Benton Jones Ph.D. (Age 57)
Sr. VP of Pharmaceutical Devel.
Comp: $346.42k

Dr. James T. Rosenbaum M.D.
Sr. VP of Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CRVS Stock - Frequently Asked Questions

Should I buy or sell Corvus Pharmaceuticals stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CRVS shares.
View CRVS analyst ratings or view top-rated stocks.
What is Corvus Pharmaceuticals' stock price forecast for 2023?: 4 Wall Street analysts have issued 12 month price objectives for Corvus Pharmaceuticals' shares. Their CRVS share price forecasts range from $3.50 to $12.00. On average, they predict the company's stock price to reach $6.63 in the next year. This suggests a possible upside of 353.8% from the stock's current price.
View analysts price targets for CRVS or view top-rated stocks among Wall Street analysts.
How have CRVS shares performed in 2023?: Corvus Pharmaceuticals' stock was trading at $0.85 at the beginning of 2023. Since then, CRVS stock has increased by 71.8% and is now trading at $1.46.
View the best growth stocks for 2023 here.
Are investors shorting Corvus Pharmaceuticals?: Corvus Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totaling 1,820,000 shares, an increase of 32.8% from the August 31st total of 1,370,000 shares. Based on an average daily trading volume, of 367,600 shares, the days-to-cover ratio is presently 5.0 days. Currently, 4.9% of the company's stock are sold short.
View Corvus Pharmaceuticals' Short Interest.
When is Corvus Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CRVS earnings forecast.
How were Corvus Pharmaceuticals' earnings last quarter?: Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14).

What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO?: 4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend.
What other stocks do shareholders of Corvus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).
When did Corvus Pharmaceuticals IPO?: (CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.
What is Corvus Pharmaceuticals' stock symbol?: Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."
How do I buy shares of Corvus Pharmaceuticals?: Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Corvus Pharmaceuticals' stock price today?: One share of CRVS stock can currently be purchased for approximately $1.46.
How much money does Corvus Pharmaceuticals make?: Corvus Pharmaceuticals (NASDAQ:CRVS) has a market capitalization of $71.50 million. The company earns $-41,310,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.
How can I contact Corvus Pharmaceuticals?: Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The official website for the company is www.corvuspharma.com. The company can be reached via phone at (650) 900-4520 or via email at llea@corvuspharma.com.

This page (NASDAQ:CRVS) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial